Hepatitis C virus and antiviral innate immunity: Who wins at tug-of-war?

World Journal of Gastroenterology

Volumn 21, Issue 13, 2015, Pages 3786-3800

  Yang, Da Rong ^a   Zhu, Hai Zhen ^a,b  

^a HUNAN UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cell culture system for hepatitis C virus; Chronic hepatitis; Hepatitis C virus; Immune evasion; Interferon; Interferonstimulated gene; RIG I; Toll like receptor; Virus host interaction

Indexed keywords

RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; AUTACOID; INTERFERON; INTERFERON REGULATORY FACTOR;

ADAPTIVE IMMUNITY; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HUMAN; IMMUNE EVASION; INNATE IMMUNITY; LIFE CYCLE; MOLECULAR RECOGNITION; NONHUMAN; REVIEW; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS DETECTION; VIRUS GENOME; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS SURVIVAL; ANIMAL; CHRONIC HEPATITIS C; HEPACIVIRUS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; PATHOGENICITY; SIGNAL TRANSDUCTION;

ANIMALS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INTERFERON REGULATORY FACTORS; INTERFERONS; SIGNAL TRANSDUCTION;

EID: 84926650523     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i13.3786     Document Type: Review

References (197)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1: 74-81 [PMID: 19207969 DOI:10.1111/j.1478-3231.2008.01934.x].
2. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36: S21-S29 [PMID: 12407573].
3. Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004; 127: S294-S302 [PMID: 15508097].
4. Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis 2009; 48: 313-320 [PMID: 19123867 DOI:10.1086/595848].
5. Liang TJ. Current progress in development of hepatitis C virus vaccines. Nat Med 2013; 19: 869-878 [PMID: 23836237 DOI:10.1038/nm.3183].
6. Rose R, Markov PV, Lam TT, Pybus OG. Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation. Infect Genet Evol 2013; 20: 418-421 [PMID: 24140473 DOI:10.1016/j.meegid.2013.09.029].
7. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104 [PMID: 19749758 DOI:10.1038/ng.447].
8. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109 [PMID: 19749757 DOI:10.1038/ng.449].
9. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI:10.1038/nature08463].
10. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI:10.1038/nature08309].
11. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345, 1345.e1-7 [PMID: 20060832 DOI:10.1053/j.gastro.2009.12.056].
12. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362 [PMID: 2523562].
13. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-327 [PMID: 24115039 DOI:10.1002/hep.26744].
14. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837-849 [PMID: 23836234 DOI:10.1038/nm.3248].
15. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-941 [PMID: 9794763].
16. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-5025 [PMID: 12356718].
17. Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol 2012; 86: 7256-7267 [PMID: 22532692 DOI:10.1128/JVI.07222-11].
18. Evans MJ, von Hahn, T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-805 [PMID: 17325668].
19. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882-886 [PMID: 19182773 DOI:10.1038/nature07684].
20. Sainz B, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18: 281-285 [PMID: 22231557 DOI:10.1038/nm.2581].
21. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589-595 [PMID: 21516087 DOI:10.1038/nm.2341].
22. Shi Q, Jiang J, Luo G. Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. J Virol 2013; 87: 6866-6875 [PMID: 23576506 DOI:10.1128/JVI.03475-12].
23. Wu X, Lee EM, Hammack C, Robotham JM, Basu M, Lang J, Brinton MA, Tang H. Cell death-inducing DFFA-like effector b is required for hepatitis C virus entry into hepatocytes. J Virol 2014; 88: 8433-8444 [PMID: 24829338 DOI:10.1128/JVI.00081-14].
24. Zeisel MB, Felmlee DJ, Baumert TF. Hepatitis C virus entry. Curr Top Microbiol Immunol 2013; 369: 87-112 [PMID: 23463198 DOI:10.1007/978-3-642-27340-7-4].
25. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463 [PMID: 17487147].
26. Rice CM. New insights into HCV replication: potential antiviral targets. Top Antivir Med 2011; 19: 117-120 [PMID: 21946389].
27. Lohmann V. Hepatitis C virus RNA replication. Curr Top Microbiol Immunol 2013; 369: 167-198 [PMID: 23463201 DOI:10.1007/978-3-642-27340-7-7].
28. Lindenbach BD. Virion assembly and release. Curr Top Microbiol Immunol 2013; 369: 199-218 [PMID: 23463202 DOI:10.1007/978-3-642-27340-7-8].
29. Mankouri J, Tedbury PR, Gretton S, Hughes ME, Griffin SD, Dallas ML, Green KA, Hardie DG, Peers C, Harris M. Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Proc Natl Acad Sci USA 2010; 107: 11549-11554 [PMID: 20534540 DOI:10.1073/pnas.0912426107].
30. Yang D, Xue B, Wang X, Yu X, Liu N, Gao Y, Liu C, Zhu H. 2-octynoic acid inhibits hepatitis C virus infection through activation of AMP-activated protein kinase. PLoS One 2013; 8: e64932 [PMID: 23741428 DOI:10.1371/journal.pone.0064932].
31. Shi S, Yu X, Gao Y, Xue B, Wu X, Wang X, Yang D, Zhu H. Inhibition of hepatitis C virus production by aptamers against the core protein. J Virol 2014; 88: 1990-1999 [PMID: 24307579 DOI:10.1128/JVI.03312-13].
32. Yang D, Meng X, Yu Q, Xu L, Long Y, Liu B, Fang X, Zhu H. Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein. Antimicrob Agents Chemother 2013; 57: 4937-4944 [PMID: 23877701 DOI:10.1128/AAC.00897-13].
33. Gao Y, Yu X, Xue B, Zhou F, Wang X, Yang D, Liu N, Xu L, Fang X, Zhu H. Inhibition of hepatitis C virus infection by DNA aptamer against NS2 protein. PLoS One 2014; 9: e90333 [PMID: 24587329 DOI:10.1371/journal.pone.0090333].
34. Yu X, Gao Y, Xue B, Wang X, Yang D, Qin Y, Yu R, Liu N, Xu L, Fang X, Zhu H. Inhibition of hepatitis C virus infection by NS5A-specific aptamer. Antiviral Res 2014; 106: 116-124 [PMID: 24713119 DOI:10.1016/j.antiviral.2014.03.020].
35. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113 [PMID: 10390360].
36. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796 [PMID: 15951748].
37. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626 [PMID: 15947137].
38. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102: 9294-9299 [PMID: 15939869].
39. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003; 125: 1808-1817 [PMID: 14724833.
40. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci USA 2006; 103: 2310-2315 [PMID: 16461899].
41. Pietschmann T, Zayas M, Meuleman P, Long G, Appel N, Koutsoudakis G, Kallis S, Leroux-Roels G, Lohmann V, Bartenschlager R. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog 2009; 5: e1000475 [PMID: 19521536 DOI:10.1371/journal.ppat.1000475].
42. Kaul A, Woerz I, Meuleman P, Leroux-Roels G, Bartenschlager R. Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J Virol 2007; 81: 13168-13179 [PMID: 17881454].
43. Zhong J, Gastaminza P, Chung J, Stamataki Z, Isogawa M, Cheng G, McKeating JA, Chisari FV. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol 2006; 80: 11082-11093 [PMID: 16956932].
44. Russell RS, Meunier JC, Takikawa S, Faulk K, Engle RE, Bukh J, Purcell RH, Emerson SU. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci USA 2008; 105: 4370-4375 [PMID: 18334634 DOI:10.1073/pnas.0800422105].
45. Delgrange D, Pillez A, Castelain S, Cocquerel L, Rouillé Y, Dubuisson J, Wakita T, Duverlie G, Wychowski C. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J Gen Virol 2007; 88: 2495-2503 [PMID: 17698659].
46. Yi M, Ma Y, Yates J, Lemon SM. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol 2007; 81: 629-638 [PMID: 17079282].
47. Scheel TK, Gottwein JM, Carlsen TH, Li YP, Jensen TB, Spengler U, Weis N, Bukh J. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. J Virol 2011; 85: 2891-2906 [PMID: 21177811 DOI:10.1128/JVI.01605-10].
48. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009; 49: 364-377 [PMID: 19148942 DOI:10.1002/hep.22673].
49. Windisch MP, Frese M, Kaul A, Trippler M, Lohmann V, Bartenschlager R. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J Virol 2005; 79: 13778-13793 [PMID: 16227297].
50. Narbus CM, Israelow B, Sourisseau M, Michta ML, Hopcraft SE, Zeiner GM, Evans MJ. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol 2011; 85: 12087-12092 [PMID: 21917968 DOI:10.1128/JVI.05843-11].
51. Date T, Kato T, Miyamoto M, Zhao Z, Yasui K, Mizokami M, Wakita T. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J Biol Chem 2004; 279: 22371-22376 [PMID: 14990575].
52. Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford JM, Nelson DR, Liu C. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 2007; 133: 1649-1659 [PMID: 17983809].
53. Ali S, Pellerin C, Lamarre D, Kukolj G. Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line. J Virol 2004; 78: 491-501 [PMID: 14671129].
54. Kato T, Date T, Miyamoto M, Zhao Z, Mizokami M, Wakita T. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 2005; 79: 592-596 [PMID: 15596851].
55. Zhu Q, Guo JT, Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 2003; 77: 9204-9210 [PMID: 12915536].
56. Fletcher NF, Yang JP, Farquhar MJ, Hu K, Davis C, He Q, Dowd K, Ray SC, Krieger SE, Neyts J, Baumert TF, Balfe P, McKeating JA, Wong-Staal F. Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology 2010; 139: 1365-1374 [PMID: 20538002 DOI:10.1053/j.gastro.2010.06.008].
57. Chang KS, Cai Z, Zhang C, Sen GC, Williams BR, Luo G. Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. J Virol 2006; 80: 7364-7374 [PMID: 16840317].
58. Long G, Hiet MS, Windisch MP, Lee JY, Lohmann V, Bartenschlager R. Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology 2011; 141: 1057-1066 [PMID: 21699799 DOI:10.1053/j.gastro.2011.06.010].
59. Frentzen A, Anggakusuma E, Hueging K, Knocke S, Ginkel C, Brown RJ, Heim M, Dill MT, Kröger A, Kalinke U, Kaderali L, Kuehnel F, Pietschmann T. Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liverderived cells. Hepatology 2014; 59: 78-88 [PMID: 23873628 DOI:10.1002/hep.26626].
60. Uprichard SL, Chung J, Chisari FV, Wakita T. Replication of a hepatitis C virus replicon clone in mouse cells. Virol J 2006; 3: 89 [PMID: 17069661].
61. Vogt A, Scull MA, Friling T, Horwitz JA, Donovan BM, Dorner M, Gerold G, Labitt RN, Rice CM, Ploss A. Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. Virology 2013; 444: 1-11 [PMID: 23777661 DOI:10.1016/j.virol.2013.05.036].
62. Lohmann V, Bartenschlager R. On the history of hepatitis C virus cell culture systems. J Med Chem 2014; 57: 1627-1642 [PMID: 24164647 DOI:10.1021/jm401401n].
63. Schwartz RE, Trehan K, Andrus L, Sheahan TP, Ploss A, Duncan SA, Rice CM, Bhatia SN. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci USA 2012; 109: 2544-2548 [PMID: 22308485 DOI:10.1073/pnas.1121400109].
64. Wu X, Robotham JM, Lee E, Dalton S, Kneteman NM, Gilbert DM, Tang H. Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog 2012; 8: e1002617 [PMID: 22496645 DOI:10.1371/journal.ppat.1002617].
65. Roelandt P, Obeid S, Paeshuyse J, Vanhove J, Van Lommel A, Nahmias Y, Nevens F, Neyts J, Verfaillie CM. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J Hepatol 2012; 57: 246-251 [PMID: 22521345 DOI:10.1016/j.jhep.2012.03.030].
66. Yang D, Liu N, Zuo C, Lei S, Wu X, Zhou F, Liu C, Zhu H. Innate host response in primary human hepatocytes with hepatitis C virus infection. PLoS One 2011; 6: e27552 [PMID: 22087337 DOI:10.1371/journal.pone.0027552].
67. Podevin P, Carpentier A, Pène V, Aoudjehane L, Carrière M, Zaïdi S, Hernandez C, Calle V, Méritet JF, Scatton O, Dreux M, Cosset FL, Wakita T, Bartenschlager R, Demignot S, Conti F, Rosenberg AR, Calmus Y. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology 2010; 139: 1355-1364 [PMID: 20600021 DOI:10.1053/j.gastro.2010.06.058].
68. Steinmann E, Pietschmann T. Cell culture systems for hepatitis C virus. Curr Top Microbiol Immunol 2013; 369: 17-48 [PMID: 23463196 DOI:10.1007/978-3-642-27340-7-2].
69. Yang D, Zuo C, Wang X, Meng X, Xue B, Liu N, Yu R, Qin Y, Gao Y, Wang Q, Hu J, Wang L, Zhou Z, Liu B, Tan D, Guan Y, Zhu H. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proc Natl Acad Sci USA 2014; 111: E1264-E1273 [PMID: 24616513 DOI:10.1073/pnas.1320071111].
70. Ploss A, Rice CM. Towards a small animal model for hepatitis C. EMBO Rep 2009; 10: 1220-1227 [PMID: 19834510 DOI:10.1038/embor.2009.223].
71. Houghton M. The long and winding road leading to the identification of the hepatitis C virus. J Hepatol 2009; 51: 939-948 [PMID: 19781804 DOI:10.1016/j.jhep.2009.08.004].
72. Alter HJ, Purcell RH, Holland PV, Popper H. Transmissible agent in non-A, non-B hepatitis. Lancet 1978; 1: 459-463 [PMID: 76017].
73. Tabor E, Gerety RJ, Drucker JA, Seeff LB, Hoofnagle JH, Jackson DR, April M, Barker LF, Pineda-Tamondong G. Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1978; 1: 463-466 [PMID: 76018].
74. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, Lanford RE, Feinstone SM, Major ME, Leroux- Roels G, Rice CM. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci USA 2006; 103: 3805-3809 [PMID: 16484368 DOI:10.1073/pnas.0511218103].
75. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997; 277: 570-574 [PMID: 9228008].
76. Institute of Medicine. Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity. Washington, DC: National Academies Press, 2011.
77. Tian ZF, Shen H, Fu XH, Chen YC, Blum HE, Baumert TF, Zhao XP. Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81. World J Gastroenterol 2009; 15: 240-244 [PMID: 19132776].
78. Tong Y, Zhu Y, Xia X, Liu Y, Feng Y, Hua X, Chen Z, Ding H, Gao L, Wang Y, Feitelson MA, Zhao P, Qi ZT. Tupaia CD81, SRBI, claudin-1, and occludin support hepatitis C virus infection. J Virol 2011; 85: 2793-2802 [PMID: 21177818 DOI:10.1128/JVI.01818-10].
79. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL, Kneteman NM. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933 [PMID: 11479625].
80. Meuleman P, Libbrecht L, De Vos, R, de Hemptinne, B, Gevaert K, Vandekerckhove J, Roskams T, Leroux-Roels G. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005; 41: 847-856 [PMID: 15791625].
81. Tesfaye A, Stift J, Maric D, Cui Q, Dienes HP, Feinstone SM. Chimeric mouse model for the infection of hepatitis B and C viruses. PLoS One 2013; 8: e77298 [PMID: 24155939 DOI:10.1371/journal.pone.0077298].
82. Kosaka K, Hiraga N, Imamura M, Yoshimi S, Murakami E, Nakahara T, Honda Y, Ono A, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Aikata H, Ochi H, Ishida Y, Tateno C, Yoshizato K, Sasaki T, Chayama K. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections. Biochem Biophys Res Commun 2013; 441: 230-235 [PMID: 24140055 DOI:10.1016/j.bbrc.2013.10.040].
83. Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, Verma IM. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010; 120: 924-930 [PMID: 20179355 DOI:10.1172/JCI40094].
84. Washburn ML, Bility MT, Zhang L, Kovalev GI, Buntzman A, Frelinger JA, Barry W, Ploss A, Rice CM, Su L. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011; 140: 1334-1344 [PMID: 21237170 DOI:10.1053/j.gastro.2011.01.001].
85. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011; 474: 208-211 [PMID: 21654804 DOI:10.1038/nature10168].
86. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, Vogt A, Catanese MT, Satoh T, Kawai T, Akira S, Law M, Rice CM, Ploss A. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 2013; 501: 237-241 [PMID: 23903655 DOI:10.1038/nature12427].
87. Billerbeck E, de Jong, Y, Dorner M, de la Fuente, C, Ploss A. Animal models for hepatitis C. Curr Top Microbiol Immunol 2013; 369: 49-86 [PMID: 23463197 DOI:10.1007/978-3-642-27340-7-3].
88. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730-737 [PMID: 15208624].
89. Rehwinkel J, Reis e Sousa C. RIGorous detection: exposing virus through RNA sensing. Science 2010; 327: 284-286 [PMID: 20075242 DOI:10.1126/science.1185068].
90. Dixit E, Boulant S, Zhang Y, Lee AS, Odendall C, Shum B, Hacohen N, Chen ZJ, Whelan SP, Fransen M, Nibert ML, Superti-Furga G, Kagan JC. Peroxisomes are signaling platforms for antiviral innate immunity. Cell 2010; 141: 668-681 [PMID: 20451243 DOI:10.1016/j.cell.2010.04.018].
91. Horner SM, Liu HM, Park HS, Briley J, Gale M. Mitochondrialassociated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus. Proc Natl Acad Sci USA 2011; 108: 14590-14595 [PMID: 21844353 DOI:10.1073/pnas.1110133108].
92. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M, Fujita T, Saito T, Lee WM, Hagedorn CH, Lau DT, Weinman SA, Lemon SM, Gale M. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 2006; 103: 6001-6006 [PMID: 16585524].
93. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008; 454: 523-527 [PMID: 18548002 DOI:10.1038/nature07106].
94. Uzri D, Gehrke L. Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J Virol 2009; 83: 4174-4184 [PMID: 19224987 DOI:10.1128/JVI.02449-08].
95. Schnell G, Loo YM, Marcotrigiano J, Gale M. Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I. PLoS Pathog 2012; 8: e1002839 [PMID: 22912574 DOI:10.1371/journal.ppat.1002839].
96. You S, Rice CM. 3' RNA elements in hepatitis C virus replication: kissing partners and long poly(U). J Virol 2008; 82: 184-195 [PMID: 17942554].
97. Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M. Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1. J Virol 2008; 82: 609-616 [PMID: 17977974].
98. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441: 101-105 [PMID: 16625202].
99. Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez- Sobrido L, Akira S, Gill MA, García-Sastre A, Katze MG, Gale M. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol 2008; 82: 335-345 [PMID: 17942531].
100. Saito T, Hirai R, Loo YM, Owen D, Johnson CL, Sinha SC, Akira S, Fujita T, Gale M. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci USA 2007; 104: 582-587 [PMID: 17190814].
101. Jiang F, Ramanathan A, Miller MT, Tang GQ, Gale M, Patel SS, Marcotrigiano J. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. Nature 2011; 479: 423-427 [PMID: 21947008 DOI:10.1038/nature10537].
102. Liu HM, Loo YM, Horner SM, Zornetzer GA, Katze MG, Gale M. The mitochondrial targeting chaperone 14-3-3ε regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity. Cell Host Microbe 2012; 11: 528-537 [PMID: 22607805 DOI:10.1016/j.chom.2012.04.006].
103. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S, Jung JU. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 2007; 446: 916-920 [PMID: 17392790].
104. Kuniyoshi K, Takeuchi O, Pandey S, Satoh T, Iwasaki H, Akira S, Kawai T. Pivotal role of RNA-binding E3 ubiquitin ligase MEX3C in RIG-I-mediated antiviral innate immunity. Proc Natl Acad Sci USA 2014; 111: 5646-5651 [PMID: 24706898 DOI:10.1073/pnas.1401674111].
105. Oshiumi H, Miyashita M, Matsumoto M, Seya T. A distinct role of Riplet-mediated K63-Linked polyubiquitination of the RIG-I repressor domain in human antiviral innate immune responses. PLoS Pathog 2013; 9: e1003533 [PMID: 23950712 DOI:10.1371/journal.ppat.1003533].
106. Oshiumi H, Miyashita M, Inoue N, Okabe M, Matsumoto M, Seya T. The ubiquitin ligase Riplet is essential for RIG-I-dependent innate immune responses to RNA virus infection. Cell Host Microbe 2010; 8: 496-509 [PMID: 21147464 DOI:10.1016/j.chom.2010.11.008].
107. Zeng W, Sun L, Jiang X, Chen X, Hou F, Adhikari A, Xu M, Chen ZJ. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell 2010; 141: 315-330 [PMID: 20403326 DOI:10.1016/j.cell.2010.03.029].
108. Jiang X, Kinch LN, Brautigam CA, Chen X, Du F, Grishin NV, Chen ZJ. Ubiquitin-induced oligomerization of the RNA sensors RIG-I and MDA5 activates antiviral innate immune response. Immunity 2012; 36: 959-973 [PMID: 22705106 DOI:10.1016/j.immuni.2012.03.022].
109. Chen W, Han C, Xie B, Hu X, Yu Q, Shi L, Wang Q, Li D, Wang J, Zheng P, Liu Y, Cao X. Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation. Cell 2013; 152: 467-478 [PMID: 23374343 DOI:10.1016/j.cell.2013.01.011].
110. Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, Hiiragi A, Dermody TS, Fujita T, Akira S. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acidinducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 2008; 205: 1601-1610 [PMID: 18591409 DOI:10.1084/jem.20080091].
111. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, Loo YM, Gale M, Akira S, Yonehara S, Kato A, Fujita T. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005; 175: 2851-2858 [PMID: 16116171].
112. Andrus L, Marukian S, Jones CT, Catanese MT, Sheahan TP, Schoggins JW, Barry WT, Dustin LB, Trehan K, Ploss A, Bhatia SN, Rice CM. Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology 2011; 54: 1901-1912 [PMID: 22144107 DOI:10.1002/hep.24557].
113. Ramachandran A, Horvath CM. Dissociation of paramyxovirus interferon evasion activities: universal and virus-specific requirements for conserved V protein amino acids in MDA5 interference. J Virol 2010; 84: 11152-11163 [PMID: 20719949 DOI:10.1128/JVI.01375-10].
114. Yang D, Meng X, Xue B, Liu N, Wang X, Zhu H. MiR-942 mediates hepatitis C virus-induced apoptosis via regulation of ISG12a. PLoS One 2014; 9: e94501 [PMID: 24727952 DOI:10.1371/journal.pone.0094501].
115. Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 2007; 82: 479-487 [PMID: 17595379].
116. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt- Jones E, Szabo G. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004; 127: 1513-1524 [PMID: 15521019].
117. Machida K, Cheng KT, Sung VM, Levine AM, Foung S, Lai MM. Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol 2006; 80: 866-874 [PMID: 16378988].
118. Wang N, Liang Y, Devaraj S, Wang J, Lemon SM, Li K. Tolllike receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J Virol 2009; 83: 9824-9834 [PMID: 19625408 DOI:10.1128/JVI.01125-09].
119. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48: 322-335 [PMID: 18506843 DOI:10.1002/hep.22306].
120. Kawasaki T, Kawai T, Akira S. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol Rev 2011; 243: 61-73 [PMID: 21884167 DOI:10.1111/j.1600-065X.2011.01048.x].
121. Funami K, Matsumoto M, Oshiumi H, Akazawa T, Yamamoto A, Seya T. The cytoplasmic 'linker region' in Toll-like receptor 3 controls receptor localization and signaling. Int Immunol 2004; 16: 1143-1154 [PMID: 15226270].
122. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009; 227: 75-86 [PMID: 19120477 DOI:10.1111/j.1600-065X.2008.00737.x].
123. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006; 176: 4894-4901 [PMID: 16585585].
124. Li K, Li NL, Wei D, Pfeffer SR, Fan M, Pfeffer LM. Activation of chemokine and inflammatory cytokine response in hepatitis C virusinfected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 2012; 55: 666-675 [PMID: 22030901 DOI:10.1002/hep.24763].
125. Dansako H, Yamane D, Welsch C, McGivern DR, Hu F, Kato N, Lemon SM. Class A scavenger receptor 1 (MSR1) restricts hepatitis C virus replication by mediating toll-like receptor 3 recognition of viral RNAs produced in neighboring cells. PLoS Pathog 2013; 9: e1003345 [PMID: 23717201 DOI:10.1371/journal.ppat.1003345].
126. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637-650 [PMID: 21616434 DOI:10.1016/j.immuni.2011.05.006].
127. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23: 275-306 [PMID: 15771572].
128. Dreux M, Garaigorta U, Boyd B, Décembre E, Chung J, Whitten- Bauer C, Wieland S, Chisari FV. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe 2012; 12: 558-570 [PMID: 23084922 DOI:10.1016/j.chom.2012.08.010].
129. Ramakrishnaiah V, Thumann C, Fofana I, Habersetzer F, Pan Q, de Ruiter, PE, Willemsen R, Demmers JA, Stalin Raj V, Jenster G, Kwekkeboom J, Tilanus HW, Haagmans BL, Baumert TF, van der Laan, LJ. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci USA 2013; 110: 13109-13113 [PMID: 23878230 DOI:10.1073/pnas.1221899110].
130. Bukong TN, Momen-Heravi F, Kodys K, Bala S, Szabo G. Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. PLoS Pathog 2014; 10: e1004424 [PMID: 25275643 DOI:10.1371/journal.ppat.1004424].
131. Preiss S, Thompson A, Chen X, Rodgers S, Markovska V, Desmond P, Visvanathan K, Li K, Locarnini S, Revill P. Characterization of the innate immune signalling pathways in hepatocyte cell lines. J Viral Hepat 2008; 15: 888-900 [PMID: 18673429 DOI:10.1111/j.1365-2893.2008.01001.x].
132. Berzsenyi MD, Roberts SK, Preiss S, Woollard DJ, Beard MR, Skinner NA, Bowden DS, Visvanathan K. Hepatic TLR2 & amp; TLR4 expression correlates with hepatic inflammation and TNF-α in HCV & amp; HCV/HIV infection. J Viral Hepat 2011; 18: 852-860 [PMID: 21050341 DOI:10.1111/j.1365-2893.2010.01390.x].
133. Riordan SM, Skinner NA, Kurtovic J, Locarnini S, McIver CJ, Williams R, Visvanathan K. Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury. Inflamm Res 2006; 55: 279-285 [PMID: 16955390].
134. Arnaud N, Dabo S, Akazawa D, Fukasawa M, Shinkai-Ouchi F, Hugon J, Wakita T, Meurs EF. Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog 2011; 7: e1002289 [PMID: 22022264 DOI:10.1371/journal.ppat.1002289].
135. Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, Mavromara P, Garcin D, Hugon J, Gatignol A, Akazawa D, Wakita T, Meurs EF. Hepatitis C virus controls interferon production through PKR activation. PLoS One 2010; 5: e10575 [PMID: 20485506 DOI:10.1371/journal.pone.0010575].
136. Garaigorta U, Chisari FV. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 2009; 6: 513-522 [PMID: 20006840 DOI:10.1016/j.chom.2009.11.004].
137. Koev G, Duncan RF, Lai MM. Hepatitis C virus IRES-dependent translation is insensitive to an eIF2alpha-independent mechanism of inhibition by interferon in hepatocyte cell lines. Virology 2002; 297: 195-202 [PMID: 12083818].
138. Shimoike T, McKenna SA, Lindhout DA, Puglisi JD. Translational insensitivity to potent activation of PKR by HCV IRES RNA. Antiviral Res 2009; 83: 228-237 [PMID: 19467267 DOI:10.1016/j.antiviral.2009.05.004].
139. Kumar A, Yang YL, Flati V, Der S, Kadereit S, Deb A, Haque J, Reis L, Weissmann C, Williams BR. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB. EMBO J 1997; 16: 406-416 [PMID: 9029159].
140. McAllister CS, Samuel CE. The RNA-activated protein kinase enhances the induction of interferon-beta and apoptosis mediated by cytoplasmic RNA sensors. J Biol Chem 2009; 284: 1644-1651 [PMID: 19028691 DOI:10.1074/jbc.M807888200].
141. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009; 21: 317-337 [PMID: 19246554 DOI:10.1093/intimm/dxp017].
142. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13: 397-411 [PMID: 23702978 DOI:10.1038/nri3452].
143. Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, Delker DA, Jo J, Bertoletti A, Hagedorn CH, Gale M. IL- 1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 2013; 9: e1003330 [PMID: 23633957 DOI:10.1371/journal.ppat.1003330].
144. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472: 481-485 [PMID: 21478870 DOI:10.1038/nature09907].
145. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 2011; 1: 519-525 [PMID: 22328912 DOI:10.1016/j.coviro.2011.10.008].
146. Zhao H, Lin W, Kumthip K, Cheng D, Fusco DN, Hofmann O, Jilg N, Tai AW, Goto K, Zhang L, Hide W, Jang JY, Peng LF, Chung RT. A functional genomic screen reveals novel host genes that mediate interferon-alpha's effects against hepatitis C virus. J Hepatol 2012; 56: 326-333 [PMID: 21888876 DOI:10.1016/j.jhep.2011.07.026].
147. Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, Kaul A, Zeuge U, Windisch MP, Trippler M, Lohmann V, Binder M, Frese M, Bartenschlager R. Identification of type I and type II interferoninduced effectors controlling hepatitis C virus replication. Hepatology 2012; 56: 2082-2093 [PMID: 22711689 DOI:10.1002/hep.25908].
148. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449: 919-922 [PMID: 17943132].
149. Fusco DN, Brisac C, John SP, Huang YW, Chin CR, Xie T, Zhao H, Jilg N, Zhang L, Chevaliez S, Wambua D, Lin W, Peng L, Chung RT, Brass AL. A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication. Gastroenterology 2013; 144: 1438-1449, 1449.e1-9 [PMID: 23462180 DOI:10.1053/j.gastro.2013.02.026].
150. Li K, Lemon SM. Innate immune responses in hepatitis C virus infection. Semin Immunopathol 2013; 35: 53-72 [PMID: 22868377 DOI:10.1007/s00281-012-0332-x].
151. Silverman RH. Viral encounters with 2', 5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol 2007; 81: 12720-12729 [PMID: 17804500].
152. Ishibashi M, Wakita T, Esumi M. 2', 5'-Oligoadenylate synthetaselike gene highly induced by hepatitis C virus infection in human liver is inhibitory to viral replication in vitro. Biochem Biophys Res Commun 2010; 392: 397-402 [PMID: 20074559 DOI:10.1016/j.bbrc.2010.01.034].
153. Kwon YC, Kang JI, Hwang SB, Ahn BY. The ribonuclease L-dependent antiviral roles of human 2', 5'-oligoadenylate synthetase family members against hepatitis C virus. FEBS Lett 2013; 587: 156-164 [PMID: 23196181 DOI:10.1016/j.febslet.2012.11.010].
154. Hinson ER, Cresswell P. The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic alpha-helix. Proc Natl Acad Sci USA 2009; 106: 20452-20457 [PMID: 19920176 DOI:10.1073/pnas.0911679106].
155. Wang S, Wu X, Pan T, Song W, Wang Y, Zhang F, Yuan Z. Viperin inhibits hepatitis C virus replication by interfering with binding of NS5A to host protein hVAP-33. J Gen Virol 2012; 93: 83-92 [PMID: 21957124 DOI:10.1099/vir.0.033860-0].
156. Helbig KJ, Eyre NS, Yip E, Narayana S, Li K, Fiches G, McCartney EM, Jangra RK, Lemon SM, Beard MR. The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A. Hepatology 2011; 54: 1506-1517 [PMID: 22045669 DOI:10.1002/hep.24542].
157. Metz P, Reuter A, Bender S, Bartenschlager R. Interferon-stimulated genes and their role in controlling hepatitis C virus. J Hepatol 2013; 59: 1331-1341 [PMID: 23933585 DOI:10.1016/j.jhep.2013.07.033].
158. Wilkins C, Woodward J, Lau DT, Barnes A, Joyce M, McFarlane N, McKeating JA, Tyrrell DL, Gale M. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 2013; 57: 461-469 [PMID: 22996292 DOI:10.1002/hep.26066].
159. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol 2011; 85: 12881-12889 [PMID: 21976647 DOI:10.1128/JVI.05633-11].
160. Zhu H, Liu C. Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J Virol 2003; 77: 5493-5498 [PMID: 12692250].
161. Yao L, Dong H, Zhu H, Nelson D, Liu C, Lambiase L, Li X. Identification of the IFITM3 gene as an inhibitor of hepatitis C viral translation in a stable STAT1 cell line. J Viral Hepat 2011; 18: e523-e529 [PMID: 21914072 DOI:10.1111/j.1365-2893.2011.01452.x].
162. Itsui Y, Sakamoto N, Kurosaki M, Kanazawa N, Tanabe Y, Koyama T, Takeda Y, Nakagawa M, Kakinuma S, Sekine Y, Maekawa S, Enomoto N, Watanabe M. Expressional screening of interferonstimulated genes for antiviral activity against hepatitis C virus replication. J Viral Hepat 2006; 13: 690-700 [PMID: 16970601].
163. Taylor DR, Puig M, Darnell ME, Mihalik K, Feinstone SM. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. J Virol 2005; 79: 6291-6298 [PMID: 15858013].
164. Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L, Block TM, Guo JT. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 2008; 82: 1665-1678 [PMID: 18077728].
165. Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 2005; 42: 702-710 [PMID: 16108059].
166. Dafa-Berger A, Kuzmina A, Fassler M, Yitzhak-Asraf H, Shemer- Avni Y, Taube R. Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin. Virology 2012; 428: 98-111 [PMID: 22520941 DOI:10.1016/j.virol.2012.03.011].
167. Horner SM, Gale M. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013; 19: 879-888 [PMID: 23836238 DOI:10.1038/nm.3253].
168. Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, Moradpour D. Nonstructural protein 3-4A: The Swiss army knife of hepatitis C virus. J Viral Hepat 2011; 18: 305-315 [PMID: 21470343 DOI:10.1111/j.1365-2893.2011.01451.x].
169. Brass V, Berke JM, Montserret R, Blum HE, Penin F, Moradpour D. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci USA 2008; 105: 14545-14550 [PMID: 18799730 DOI:10.1073/pnas.0807298105].
170. Horner SM, Park HS, Gale M. Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0. J Virol 2012; 86: 3112-3120 [PMID: 22238314 DOI:10.1128/JVI.06727-11].
171. Foy E, Li K, Wang C, Sumpter R, Ikeda M, Lemon SM, Gale M. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145-1148 [PMID: 12702807].
172. Foy E, Li K, Sumpter R, Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM, Gale M. Control of antiviral defenses through hepatitis C virus disruption of retinoic acidinducible gene-I signaling. Proc Natl Acad Sci USA 2005; 102: 2986-2991 [PMID: 15710892].
173. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. Cardifis an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 1167-1172 [PMID: 16177806].
174. Baril M, Racine ME, Penin F, Lamarre D. MAVS dimer is a crucial signaling component of innate immunity and the target of hepatitis C virus NS3/4A protease. J Virol 2009; 83: 1299-1311 [PMID: 19036819 DOI:10.1128/JVI.01659-08].
175. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci USA 2005; 102: 17717-17722 [PMID: 16301520].
176. Bellecave P, Sarasin-Filipowicz M, Donzé O, Kennel A, Gouttenoire J, Meylan E, Terracciano L, Tschopp J, Sarrazin C, Berg T, Moradpour D, Heim MH. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 2010; 51: 1127-1136 [PMID: 20044805 DOI:10.1002/hep.23426].
177. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M, Lemon SM. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005; 102: 2992-2997 [PMID: 15710891].
178. Ferreon JC, Ferreon AC, Li K, Lemon SM. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J Biol Chem 2005; 280: 20483-20492 [PMID: 15767257].
179. Zhang Z, Kim T, Bao M, Facchinetti V, Jung SY, Ghaffari AA, Qin J, Cheng G, Liu YJ. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity 2011; 34: 866-878 [PMID: 21703541 DOI:10.1016/j.immuni.2011.03.027].
180. Dabo S, Meurs EF. dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses 2012; 4: 2598-2635 [PMID: 23202496 DOI:10.3390/v4112598].
181. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-227 [PMID: 9143277].
182. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-110 [PMID: 10390359].
183. Noguchi T, Satoh S, Noshi T, Hatada E, Fukuda R, Kawai A, Ikeda S, Hijikata M, Shimotohno K. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells. Microbiol Immunol 2001; 45: 829-840 [PMID: 11838900].
184. Eksioglu EA, Zhu H, Bayouth L, Bess J, Liu HY, Nelson DR, Liu C. Characterization of HCV interactions with Toll-like receptors and RIG-I in liver cells. PLoS One 2011; 6: e21186 [PMID: 21695051 DOI:10.1371/journal.pone.0021186].
185. Horner SM, Gale M. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res 2009; 29: 489-498 [PMID: 19708811 DOI:10.1089/jir.2009.0063].
186. Pang PS, Planet PJ, Glenn JS. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One 2009; 4: e6579 [PMID: 19668364 DOI:10.1371/journal.pone.0006579].
187. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-7039 [PMID: 18467494 DOI:10.1073/pnas.0707882105].
188. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, Papassotiropoulos A, Roth V, Heim MH. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-1031 [PMID: 21111740 DOI:10.1053/j.gastro.2010.11.039].
189. Chen L, Borozan I, Sun J, Guindi M, Fischer S, Feld J, Anand N, Heathcote J, Edwards AM, McGilvray ID. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 2010; 138: 1123-1133.e1-3 [PMID: 19900446DOI:10.1053/j.gastro.2009.10.046].
190. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, Soejima Y, Shirabe K, Matsuura Y, Maehara Y. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585, 1585.e1-3 [PMID: 20708617 DOI:10.1053/j.gastro.2010.07.058].
191. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, Nattermann J, Oldenburg J, Sauerbruch T, Spengler U. Interferon-lambda serum levels in hepatitis C. J Hepatol 2011; 54: 859-865 [PMID: 21145813 DOI:10.1016/j.jhep.2010.08.020].
192. Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, Clark PJ, Patel K, Muir AJ, McHutchison JG, Schlaak JF, Trippler M, Shivakumar B, Masur H, Polis MA, Kottilil S. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 2012; 56: 444-454 [PMID: 22331604 DOI:10.1002/hep.25647].
193. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164-171 [PMID: 23291588 DOI:10.1038/ng.2521].
194. Zhu H, Butera M, Nelson DR, Liu C. Novel type I interferon IL- 28A suppresses hepatitis C viral RNA replication. Virol J 2005; 2: 80 [PMID: 16146571].
195. Kelly C, Klenerman P, Barnes E. Interferon lambdas: The next cytokine storm. Gut 2011; 60: 1284-1293 [PMID: 21303914 DOI:10.1136/gut.2010.222976].
196. Lange CM, Jacobson IM, Rice CM, Zeuzem S. Emerging therapies for the treatment of hepatitis C. EMBO Mol Med 2014; 6: 4-15 [PMID: 24106239].
197. Lange CM, Zeuzem S. Perspectives and challenges of interferonfree therapy for chronic hepatitis C. J Hepatol 2013; 58: 583-592 [PMID: 23104162 DOI:10.1016/j.jhep.2012.10.019].